Anesthesia alters NO-mediated functional hyperemia.
Many properties of nitric oxide, NO, (localization, diffusiveness, half-life, vasodilatory affects) have supported its potential role in mediating the link between local cerebral activity and blood flow. However, evidence that both supports and refutes a role for NO in functional hyperemia have been presented. The present study employed multiple nitric oxide synthase inhibitors, two anesthetic regimes and laser-Doppler flowmetry to test the hypothesis that NO is critically involved in mediating the functional hyperemic response within rodent whisker-barrel cortex (WBC). In urethane anesthetized animals, functional hyperemic responses were obtained both before and after 1 mg/kg atropine infusion, 30 mg/kg i.v. L-NAME (N-Nitro-L-arginine methylester) infusion, 30 mg/kg L-NA (N-Nitro-L-arginine) infusion or 25 mg/kg 7-NI (7-nitroindazole). L-NAME was also tested in a group of animals pretreated with halothane before urethane anesthesia. Neither the magnitude of the blood flow response nor its time course was altered by NO blockade or atropine administration when compared to pre-infusion controls in urethane anesthetized rats. In contrast, animals that were pretreated with halothane exhibited a 33% inhibition of functional hyperemia after L-NAME administration. Taken together, these data do not support a primary role for NO in rat WBC functional hyperemia and suggest that previous reports of inhibition may have been secondary to the anesthesia employed.
Gerrits
R J
RJ
Department of Physiology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Stein
E A
EA
Greene
A S
AS
D000768:Anesthesia, General; D018685:Anesthetics, Inhalation / Q000494:pharmacology*; D018686:Anesthetics, Intravenous / Q000494:pharmacology; D000818:Animals; D001285:Atropine / Q000494:pharmacology; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006221:Halothane / Q000494:pharmacology*; D006940:Hyperemia / Q000503:physiopathology*; D007191:Indazoles / Q000494:pharmacology; D008297:Male; D018727:Muscarinic Antagonists / Q000494:pharmacology; D019331:NG-Nitroarginine Methyl Ester / Q000494:pharmacology; D009419:Nerve Tissue Proteins / Q000037:antagonists & inhibitors*; D009569:Nitric Oxide / Q000502:physiology*; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors; D019335:Nitroarginine / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D011976:Receptors, Muscarinic / Q000187:drug effects; D013003:Somatosensory Cortex / Q000098:blood supply*; D014110:Touch / Q000502:physiology*; D014520:Urethane / Q000494:pharmacology; D014664:Vasodilation; D014738:Vibrissae / Q000294:innervation*
D018685:Anesthetics, Inhalation; D018686:Anesthetics, Intravenous; D004791:Enzyme Inhibitors; D007191:Indazoles; D018727:Muscarinic Antagonists; D009419:Nerve Tissue Proteins; D011976:Receptors, Muscarinic; D019335:Nitroarginine; D009569:Nitric Oxide; D014520:Urethane; D001285:Atropine; D019001:Nitric Oxide Synthase; D006221:Halothane; C080122:7-nitroindazole; D019331:NG-Nitroarginine Methyl Ester